Loading stock data…
STRO
$37.32-1.07 (-2.79%)
Sutro Biopharma, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sutro Biopharma, Inc. in the Healthcare sector is trading at $37.32. The stock is currently near its 52-week high of $39.74, remaining 157.0% above its 200-day moving average. Technical signals show overbought RSI of 72 and bullish MACD crossover, explaining why STRO maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 72) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$37.32
Potential Upside
5%
Whystock Fair Value$39.19
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$35.73-4.3%
Range$9.00 – $55.00
Fundamentals
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conju...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$588.63M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.31
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
157.56%
Volume
Today's trading volume
235,602
Recent News
Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates
Ocugen (OCGN) delivered earnings and revenue surprises of -12.57% and +27.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Citizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead Program
Sutro Biopharma, Inc. (NASDAQ:STRO) is one of the best performing small cap stocks so far in 2026. Citizens lifted the price target on Sutro Biopharma, Inc. (NASDAQ:STRO) to $41 from $35 on April 23, reaffirming an Outperform rating on the shares. The firm told investors in a research note that the recent AACR presentations highlighted […]
Meta downgraded, Qualcomm upgraded: Wall Street's top analyst calls
Meta downgraded, Qualcomm upgraded: Wall Street's top analyst calls
Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now
Sutro Biopharma Inc. (NASDAQ:STRO) is one of the tiny stocks that are on fire right now. On March 23, Sutro Biopharma reported its full-year 2025 financial results, highlighting a strengthened balance sheet and significant clinical milestones for its antibody-drug conjugate/ADC platform. The company ended 2025 with $141.4 million in cash and marketable securities, which, when […]
Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.